Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Apellis Pharmaceuticals Is Getting Hammered Today

By Cory Renauer – Sep 10, 2021 at 10:52AM

Key Points

  • One out of two identical studies with the company's geographic atrophy candidate didn't achieve statistical significance on its primary endpoint.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Conflicting clinical trial results for the company's lead candidate are to blame.

What happened

Shares of Apellis Pharmaceuticals (APLS 0.55%), a biopharmaceutical company focused on rare diseases, are sliding lower on Friday. Investors responding to conflicting clinical trial data for the company's experimental blindness prevention drug pushed the stock 47.94% lower as of 10:25 a.m. EDT on Friday.

So what 

Apellis earned Food and Drug Administration approval for its first drug, Empaveli, this May so there's still a lot riding on pegcetacoplan, the next potential new drug emerging from the company's pipeline. Unfortunately, pegcetacoplan produced clinical trial results that weren't as convincing as investors had hoped.

Frustrated investor checking stocks on a computer.

Image source: Getty Images.

A pair of identical phase 3 studies named Oaks and Derby tested injections of pegcetacoplan on over 1,200 patients with geographic atrophy. In the Oaks trial, a year of treatment with pegcetacoplan significantly reduced the growth of retinal lesions compared to a placebo. Unfortunately, reductions recorded in the Derby trial weren't strong enough to be considered statistically significant.

Now what

Geographic atrophy is an advanced and aggressive form of age-related macular degeneration, or AMD. Effective treatments that prevent the progression of AMD have been generating blockbuster sales for years, but there still aren't any treatments approved to treat geographic atrophy specifically. 

Results from the Derby trial were close enough to a level considered statistically significant that Apellis Pharmaceuticals is going to forge ahead with pegcetacoplan. The biotech plans to submit a new drug application to the FDA for the treatment of geographic atrophy in the first half of 2022.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Apellis Pharmaceuticals, Inc. Stock Quote
Apellis Pharmaceuticals, Inc.
$51.24 (0.55%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.